Deniz Akay-Güven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deniz Akay-Güven has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ayse Batirel
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Istanbul Kartal Dr. Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye
1 shared publication - Elif Sargin Altunok
Departmen of Infectious Diseases and Clinical Microbiology, University of Health Sciences Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Türkiye
1 shared publication - Sultan Öztürk-Aydemir
Saglık Bilimleri Üniversitesi İstanbul Kartal Dr. Lütfi Kırdar Sehir Hastanesi, İnfeksiyon Kontrol Hemsireligi, İstanbul, Türkiye
1 shared publication - Zeynep Ersoz
Istanbul Kartal Dr. Lütfi Kırdar City Hospital
1 shared publication
Latest Publications
- Open Access
- 28 September 2022
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 35 (3) , 191-195
Does COVID-19 Increase the Risk of Central-Line-Associated Bloodstream Infections?
Objectives: All over the world, there has been a rapid and significant increase in the number of critically ill patients requiring mechanical ventilation, which was over the capacity of the intensive care units (ICU). This resulted in an increased risk of healthcare-associated infections. The most significant increase was in central-line-associated bloodstream infections (CLABSI). Our study aimed to determine the effect of COVID-19 infection on CLABSI rates in patients in the COVID-ICU and the factors affecting it. Methods: Adult patients hospitalized in the ICU between January 01, 2021, and December 31, 2021, and diagnosed with CLABSI were evaluated retrospectively. Only the first infection data of patients diagnosed with more than one CLABSI during hospitalization were included in the study. The patients were divided into two groups COVID-ICU and general ICU patients and were compared in terms of infection rate, risk factors, and agent distributions. Results: Twenty-two patients in the COVID-ICU and 32 patients in the general ICUs were diagnosed with CLABSI, and the infection rates were 2.05 and 1.03, respectively. The patients in the COVID-ICU had a shorter length of stay in the ICU and a significantly shorter time from ICU admission to CLABSI diagnosis. There was no difference in mortality between the two groups. Infections caused by Gram-negative microorganisms developed most frequently in both groups, and Acinetobacter baumannii was the most frequent among them. Conclusion: CLABSI is seen more frequently and earlier in patients followed in the COVID-ICU. According to our study, this situation did not significantly affect mortality. To prevent CLABSI in COVID-ICUs and improve health care quality, additional management strategies must be determined, and close data monitoring is needed.
- 28 September 2022
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 35 (3) , 191-195
Open AccessDoes COVID-19 Increase the Risk of Central-Line-Associated Bloodstream Infections?
Objectives: All over the world, there has been a rapid and significant increase in the number of critically ill patients requiring mechanical ventilation, which was over the capacity of the intensive care units (ICU). This resulted in an increased risk of healthcare-associated infections. The most significant increase was in central-line-associated bloodstream infections (CLABSI). Our study aimed to determine the effect of COVID-19 infection on CLABSI rates in patients in the COVID-ICU and the factors affecting it. Methods: Adult patients hospitalized in the ICU between January 01, 2021, and December 31, 2021, and diagnosed with CLABSI were evaluated retrospectively. Only the first infection data of patients diagnosed with more than one CLABSI during hospitalization were included in the study. The patients were divided into two groups COVID-ICU and general ICU patients and were compared in terms of infection rate, risk factors, and agent distributions. Results: Twenty-two patients in the COVID-ICU and 32 patients in the general ICUs were diagnosed with CLABSI, and the infection rates were 2.05 and 1.03, respectively. The patients in the COVID-ICU had a shorter length of stay in the ICU and a significantly shorter time from ICU admission to CLABSI diagnosis. There was no difference in mortality between the two groups. Infections caused by Gram-negative microorganisms developed most frequently in both groups, and Acinetobacter baumannii was the most frequent among them. Conclusion: CLABSI is seen more frequently and earlier in patients followed in the COVID-ICU. According to our study, this situation did not significantly affect mortality. To prevent CLABSI in COVID-ICUs and improve health care quality, additional management strategies must be determined, and close data monitoring is needed.